Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)

The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second- or third-line treatment for elderly Japanese patients with non-small-cell lung cancer (NSCLC). The patients eligible for this phase II tria...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mol Clin Oncol
Main Authors: Miyawaki, Masayoshi, Naoki, Katsuhiko, Yoda, Satoshi, Nakayama, Sohei, Satomi, Ryosuke, Sato, Takashi, Ikemura, Shinnosuke, Ohgino, Keiko, Ishioka, Kota, Arai, Daisuke, Namkoong, Ho, Otsuka, Kengo, Miyazaki, Masaki, Tani, Tetsuo, Kuroda, Aoi, Nishino, Makoto, Yasuda, Hiroyuki, Kawada, Ichiro, Koh, Hidefumi, Nakamura, Morio, Terashima, Takeshi, Sakamaki, Fumio, Sayama, Koichi, Betsuyaku, Tomoko, Soejima, Kenzo
Format: Artigo
Sprog:Inglês
Udgivet: D.A. Spandidos 2017
Fag:
Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5403701/
https://ncbi.nlm.nih.gov/pubmed/28451422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1154
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker